A new model of reversible superior sagittal sinus thrombosis in rats

Wang, Jianzhen; Ji, Xunming; Li, Feng; Luo, Yumin; He, Xin; Guo, Miao; Li, Shenmao; Miao, Zhongrong; Zhu, Fengshui; Xuan, Yang

doi:10.1016/j.brainres.2007.08.070

Cited by 11 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laser Doppler flowmetry has been commonly used to evaluate variation in local cerebral blood flow as an indirect measure of thrombosis burden 57 . MRV is a contrast‐free and non‐invasive technique whose benefits are to assess thrombus size after its formation and recanalization rate over weeks 49 . Intravital microscopy can be used to confirm in vivo thrombosis using fluorescein, 41,50 or imaging probe targeting thrombus 36 .…”

Section: Relevant Endpoints For Cvst Modelsmentioning

confidence: 99%

“…57 MRV is a contrast-free and non-invasive technique whose benefits are to assess thrombus size after its formation and recanalization rate over weeks. 49 Intravital microscopy can be used to confirm in vivo thrombosis using fluorescein, 41,50 or imaging probe targeting thrombus. 36 In fact, intravital microscopy offers the opportunity to monitor thrombosis over time using injection of labeled fluorescent thrombus.…”

Section: Rele Vant Endp Oints For C Vs T Model Smentioning

confidence: 99%

“…These models aim to induce a more physiological thrombus. With the exception of the model developed by Wang et al, 49 most of these are combined models. They include ligation 39,[41][42][43][44] or photothrombosis 50 around the SSS to limit uncontrolled dispersion of the thrombogenic solution into venous circulation, as well as in other organs.…”

Section: Thrombogenic Substance-induced Cvstmentioning

confidence: 99%

See 2 more Smart Citations

State of the art in cerebral venous sinus thrombosis animal models

Bourrienne

Gay

Mazighi

et al. 2022

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Cerebral venous sinus thrombosis (CVST) is an uncommon location of venous thromboembolism (VTE) that represents a distinct cause of stroke primarily affecting young adults. 1,2 Predisposing factors for CVST are multiple, including those described in VTE and specific local causes (regional infections, brain tumors, and cranial trauma). 3 Beyond thrombosis, CVST-related parenchymal injuries include edema, ischemic strokes, and intra-cerebral hemorrhage (ICH; i.e., parenchymal/subdural hematomas and subarachnoid hemorrhages), which are identified in 40%-60% of patients. [4][5][6][7] Diagnosis and prognosis are still challenging due to the non-specificity and high variability of clinical course. Clinical symptoms result from increased intracranial pressure due to impaired venous drainage and CVST-related brain injury. Clinical symptoms range from isolated headaches (the most frequent one at presentation ≈90%), to focal deficits, seizure, and coma. 4,5,7,8 Recent studies reported higher incidence of CVST than previously estimated (13-17.5 vs. 3-5 million per year, respectively) with an overall death and dependency rate ≈15%. 1,2,6 This may be the result, at least in part, of the improved

show abstract

Section: Relevant Endpoints For Cvst Modelsmentioning

confidence: 99%

Section: Rele Vant Endp Oints For C Vs T Model Smentioning

confidence: 99%

Section: Thrombogenic Substance-induced Cvstmentioning

confidence: 99%

See 1 more Smart Citation

State of the art in cerebral venous sinus thrombosis animal models

Bourrienne

Gay

Mazighi

et al. 2022

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

A multicenter single‐arm objective performance criteria trial evaluating the efficacy and safety of a dedicated venous sinus thrombectomy device for severe cerebral venous sinus thrombosis

Yusuying,

Wu,

et al. 2024

Neuroprotection

View full text Add to dashboard Cite

AimApproximately 21% of patients with cerebral venous sinus thrombosis (CVST) are refractory to anticoagulation treatment and face poor prognosis. These patients may benefit from endovascular therapy. Although numerous studies have reported promising results with endovascular therapy, it remains challenging to obtain convincing evidence of its efficacy and safety due to the unique challenges posed by CVST, such as larger vessel diameters, distinct pathophysiology, and substantial clot burden. Therefore, dedicated endovascular therapy tools should be developed specifically for CVST. This study aimed to evaluate the efficacy and safety of a dedicated venous sinus thrombectomy device in patients with acute or subacute CVST.MethodsThis prospective, multicenter, single‐arm trial utilized an objective performance criterion design. Enrolled patients received treatment with a dedicated venous sinus thrombectomy device to recanalize occluded sinuses or veins. The primary objective was to compare the immediate postoperative recanalization rate with a preset target value to determine whether the device met the clinical application needs. The trial plans to enroll 146 patients from 11 tertiary medical centers in China.DiscussionThis trial is expected to fill a critical gap in endovascular treatments for CVST and support the development of reliable, dedicated thrombectomy devices for future studies.

show abstract